Abstract
Objective: The aim of this study was to determine the health impact and cost-effectiveness of introducing a human papillomavirus (HPV) vaccination programme with a quadrivalent vaccine alongside the existing cervical cancer screening programme in comparison to the current context in Italy. Methods: A US Markov model was adapted to the Italian context, assuming under base case 80% vaccine coverage rate, lifetime duration of protection in a cohort of girls aged 12 years and discount rates of 1.5% and 3% for health benefits and costs, respectively, and estimating direct medical costs. Results: The HPV vaccination in association with the current screening programme would allow to avoid 1432 cases of cervical cancer (- 63.3%) and 513 deaths (- 63.4%) compared to screening only, with an incremental cost-effectiveness ratio (ICER) of €9569 per additional quality-adjusted life-year (QALY) gained. The sensitivity analysis highlighted that this model was robust to all parameters presenting uncertainties as the ICERs ranged from €2,781 to €48,122 per QALY gained. Conclusion: This study showed that HPV vaccination in adolescent girls would be a beneficial and cost-effective public health programme in Italy.
Original language | English |
---|---|
Pages (from-to) | 370-376 |
Number of pages | 7 |
Journal | Gynecologic Oncology |
Volume | 112 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2009 |
Keywords
- Adolescents
- Cervical cancer
- Cost-effectiveness analysis
- Human papillomavirus
- Italy
- Vaccination
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Oncology